_256_384.jpg)
Drug Approval | February 10, 2025
Briefs: Caplin Point Laboratories, Hikal and Cipla
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.
The inspection was concluded with zero observations
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
Key takeaways of recent quarter & conference call highlights
Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.
The Board of Directors of Caplin Point Laboratories at its meeting have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
The approval allows it to market its products in the country
EPS climbs to Rs 9.25 for the quarter
Subscribe To Our Newsletter & Stay Updated
